Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2025-4499

Published: 2025

Journal Articles

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue, Oluwatayo Adeoye, Ayodeji Johnson, Arushi Khurana, Jithma Abeykoon, Urshila Durani, Mazie Tsang, Allison Rosenthal, Talal Hilal, Javier Munoz, Patrick Johnston, Han Tun, Grzegorz Nowakowski, James Cerhan, Richard Godby, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2025-4494

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Blood (2025) 146 (Supplement 1): 479.

https://doi.org/10.1182/blood-2025-479

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos

Blood (2025) 146 (Supplement 1): 476.

https://doi.org/10.1182/blood-2025-476

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Jose Villasboas Bisneto, John M. Burke, Aung Tun, Steve Liu, Jeff Sharman, Juliana Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Javier Munoz, Furhan Yunus, Ian Flinn, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2025-1807

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot

Blood (2025) 146 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2025-1006

Published: 2025

Journal Articles

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

Amir Ali, Pallawi Torka, Yucai Wang, Tara Graff, Erin Mulvey, Yumeng Zhang, Monika Jun, Abualbishr Alshreef, Alex Mutebi, Anthony Wang, David Tybor, Lynn Huynh, Angela Lax, Tychell Branchcomb, Mei Sheng Duh, Javier Munoz, Muhamad Alhaj Moustafa, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 8075.

https://doi.org/10.1182/blood-2025-8075

Published: 2025

Journal Articles

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 402.

https://doi.org/10.1182/blood-2025-402

Published: 2025

Journal Articles

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Blood (2025) 146 (Supplement 1): 401.

https://doi.org/10.1182/blood-2025-401

Published: 2025

Journal Articles

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes

Angel Luis OROSCO TTAMINA, Javier Munoz, Katalin Kelemen, Jeanne Palmer, Aref Al-Kali, Candido Rivera, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi, Cecilia Arana Yi

Blood (2025) 146 (Supplement 1): 7315.

https://doi.org/10.1182/blood-2025-7315

Published: 2025

Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2025-3704

Published: 2025

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Chad M. Williams, Joshua Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2025) 145 (20): 2303–2311.

https://doi.org/10.1182/blood.2024027347

Published: 2025

Includes: Supplemental data

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7760.

https://doi.org/10.1182/blood-2024-203876

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7757.

https://doi.org/10.1182/blood-2024-203540

Published: 2024

Journal Articles

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Marc Hoffmann, Theodoros Vassilakopoulos, Javier Munoz, Jason R. Westin, Maria Bouzani, Wojciech Jurczak, Michał Kwiatek, Alejandro Berkovits, Tai-Chung Huang, Akshay Sudhindra, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 1742.2.

https://doi.org/10.1182/blood-2024-203185

Published: 2024

Journal Articles

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

Arnaud Amzallag, Tara Basavanhally, Jason R. Westin, Marc Hoffmann, Theodoros P. Vassilakopoulos, Javier Munoz, Grzegorz S. Nowakowski, Floriane Boucaud, Matt Stokes, Akshay Sudhindra, Anita K. Gandhi, Mark Kaplan

Blood (2024) 144 (Supplement 1): 579.

https://doi.org/10.1182/blood-2024-203135

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2024-200408

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only